



Molecularly Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidine

Irina Panovska-Stavridis^{1*}, M Ivanovski¹, S. Trajkova¹, A Pivkova-Veljanovska¹, M Popova-Labaceska¹, N Matevska-Geshovska², P Noveski³, D Plaseska-Karanfilska³, L Cevreska¹ and AJ Dimovski²

¹Department of Medicine, University Clinic of Hematology, Skopje

²Department of Pharmacy, Center of Biomolecular Pharmaceutical Analyses, Skopje

³Department of Engineering, Research Centre for Genetic Engineering and Biotechnology, Skopje

Abstract

Myelodysplastic Syndrome (MDS) is a diverse group of clonal hematologic neoplasms. The only curative treatment for MDS is allogeneic Stem Cell Transplantation (SCT). Epigenetic changes play an important role in the pathogenesis of MDS and treatment with DNA methyl transferase inhibitors, Azacitidine significantly prolong the survival of high-risk MDS patients.

Introduction

Here we report a case of a 58-year-old male presented with pancytopenia, macrocytosis, and hyperplastic bone marrow with 3-lineage dysplasia with ~14% of myeloid blasts. Cytogenetic studies with G banding showed normal karyotype. MLPA screening for most predictive cytogenetic abnormalities of MDS showed loss of the Y chromosome, later confirmed with Quantitative Fluorescent (QF)-PCR and specific MLPA for Y chromosome, showing loss of the Y chromosome in >80% of cells. He was diagnosed with MDS-RAEB2 according to 2008 WHO classification and stratified into high risk group (IPSS score 5). Unrelated allogeneic SCT was planned and bridging treatment with Azacitidine at a dose of 75mg/m²/daily subcutaneously for 7 days every 28 days was initiated. Hematologic improvements, according to the International Working Group 2006 criteria, were observed after 4 cycles of azacitidine treatment. After 6 cycles, complete hematological remission was achieved. Interestingly, molecular analyses performed after the 8th cycle showed normal presence of Y chromosome indicating a cytogenetic remission, molecularly confirmed. Maintenance treatment with Azacitidine was assigned, and the scheduled SCT was postponed.

Case Presentation

Experience from our case showed that the loss of the Y chromosome was related to the disease onset, and indicated that Azacitidine might be considered as effective treatment for MDS cases associated with good cytogenetic profile.

Myelodysplastic Syndrome (MDS) comprises a diverse group of clonal hematologic neoplasms characterized by a profound heterogeneity in morphologic presentation, clinical course, and cytogenetic features [1,2]. The majority of patients with MDS present with symptoms related to anemia; however, bleeding and infection are the most common causes of death. The median age of diagnosis is 72 and the median survival is 2.5 years [1-3]. About 50% of the patients display clonal chromosomal abnormalities, which are some of the most important prognostic parameters of MDS patients [4-6]. Patients, whose only chromosomal abnormality is a loss of the Y chromosome (LOY) have a very good prognosis according to the International Prognostic Scoring System (IPSS-R). The association between the LOY and MDS is debated because both phenomena are related to aging [6,7]. The only potentially curative treatment for MDS is allogeneic Stem Cell Transplantation (SCT) [1]. Moreover, epigenetic changes play an important role in the pathogenesis of MDS and the treatment with DNA methyl transferase inhibitor Azacitidine and Decitabine significantly prolongs the survival of intermediate and high-risk MDS patients [1,8].

In December 2015, a 58 year old male was referred to our Institution due to pancytopenia, macrocytosis and physical complaints related to anemia. The initial peripheral blood examination revealed anemia with hemoglobin (Hg) levels of 9.2 g/dl, decreased White Blood Cell (WBC) count of 3.4x10⁹/l with normal absolute neutrophil count (ANC) of 1.6 x10⁹/l, thrombocytopenia

OPEN ACCESS

*Correspondence:

Irina Panovska-Stavridis,
Department of Medicine, University
Clinic for Hematology, Majka Tereza 17,
1000, Skopje,
E-mail: dr_irina@yahoo.com

Received Date: 12 May 2017

Accepted Date: 17 Jan 2018

Published Date: 25 Jan 2018

Citation:

Panovska-Stavridis I, Ivanovski M, Trajkova S, Pivkova-Veljanovska A, Popova-Labaceska M, Matevska-Geshovska N, et al. Molecularly Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidine. *Am J Leuk Res.* 2018; 2(1): 1008.

Copyright © 2018 Irina Panovska-Stavridis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1: Hematologic improvements and the International Working Group (IWG) 2006-response criteria with cycles of the Azacitidine treatment.

Cycle of Azacitidine	Hb g/dl	Plt x10 ⁹ /l	RBC transfusion	BM blasts	Hematological improvements		IWG 2006 response criteria
					HI-E (>1.5g/dl)	HI-P (>30x10 ⁹ /l)	
0	8.2	38	+	14%	-	-	SD
1	8	35	+	ND	-	-	SD
2	9.1	26	-	ND	-	-	SD
3	9.7	44	-	ND	+	+	HI-P
4	10.1	93	-	ND	+	+	HI-E and HI-P
5	14.2	185	-	ND	+	+	HI-E and HI-P
6	16	250	-	3.20%	+	+	marrow CR with HI-E and HI-P
7	16.6	220	-	ND	+	+	HI-E and HI-P
8	15.9	152	-	ND	+	+	marrow CR with HI-E and HI-P
9	15.8	188	-	ND	+	+	SD

CR: Complete Remission; SD: Stable Disease; HI-E: Hematological Improvement-Erythroid; HI-P: Hematological Improvement-Platelet




Figure 1: Bonemarrow biopsy before Azacitidine treatment: hyperplastic marrow with three lineage hyperplasia and an increased number of mononuclear blast cells (Hematoxylin– Eosin stain x 200).

with Platelet (Plt) count of 68 x10⁹/l, and 0% blasts, 3% bands form, 47% segmented neutrophils, 3% monocytes, 1% myelocytes and 46% lymphocytes. The bone marrow biopsy showed a hyperplastic bone marrow with 3-lineage dysplasia (Figure 1) and increased number (14%) of mononuclear myeloid blasts as determined by immuno histochemistry. On physical examination, he was pale with palpable spleen at 1cm under the rib cage (measured 14cm by abdominal ultrasound examination). Flow-cytometry showed the presence of 2% CD34+ blast cells in the peripheral blood. The cytogenetic studies of the bone marrow with G banding showed normal karyotype. The multiplex ligation-dependent probe amplification (MLPA) screening for most predictive cytogenetic abnormalities in MDS [SALSA MLPA P414 MDS probe mix, MRC Holland, 1057 DL Amsterdam, the Netherlands] indicated a loss of the Y chromosome as the only chromosomal abnormality. This finding was later confirmed with Quantitative Fluorescent PCR and specific MLPA for the Y chromosome, showing a loss of the Y chromosome in >80% of the cells (Figure 2a). The quantitative fluorescent PCR methodology included co-amplification of homologous sequences on chromosome Y and other chromosomes using multiplex quantitative fluorescent (QF) PCR followed by automatic detection and analysis on ABI 3500 Genetic Analyzer [9].

These results were not consistent with the cytogenetic results and we asked the referent cytogenetic lab to reevaluate their results. They analyzed 20 metaphase cells of which 8 were with a normal




Figure 2: Quantitative Fluorescent PCR for the analysis of Y chromosome loss at diagnosis a) 80% loss] and after 8 cycles of Azacitidine treatment b) normal content].

karyotype and the rest had a very heterogeneous karyotype with 44 or 45 chromosomes. Since individual metaphases had a loss/gain of different chromosomes and there were no unique abnormality pertinent to at least three cells, the presence of a clonal cell population or a mosaicism could not be determined conclusively [10]. The patient was diagnosed with MDS-RAEB2 according to the 2008

WHO classification. The risk group was classified as high (score 5) in IPSS, high in the revised IPSS (IPSS-R), associated with a median overall survival of 21 months, and 52% probability of 2 year AML progression [3,5]. Allogeneic SCT was the best estimated treatment for our patient. HLA typing revealed no identical siblings [1,3,8,11]. Unrelated allogeneic SCT was planned and bridging treatment with Azacitidine at a dose of 75mg/m²/daily subcutaneously for 7 days every 28 days was initiated in April, 2016. The patient required a transfusion of more than 4 units of blood cells for a period of 8 weeks before being treated with Azacitidine. The risk group the patient was assigned for the Azacitidine treatment was classified as intermediate [11].

Hematologic responses after 4 cycles of the Azacitidine treatment were considered to be hematological improvements with erythroid (HI-E) and platelet (HI-P) responses according to the International Working Group (IWG) 2006-response criteria [12]. Table 1 shows IWG responses and hematologic improvements determined just before each cycle of the Azacitidine treatment. Transient neutropenia and even lower platelet count were present until the completion of the third cycle of treatment. Afterwards, a gradual increase in blood cells count was noted and the patient became transfusion independent.

The efficacy of the Azacitidine treatment was scored as a marrow complete remission (marrow CR) with HI-E and HI-P responses (Table1). Hematologic improvements were observed after the 4th cycle of treatment and a complete hematological remission and marrow CR were achieved after the 6th cycle. The percentage of myeloblasts after the 6th cycle was 3.2%. Molecular analyses performed after the 8th cycle showed normal presence of the Y chromosome indicating a molecularly confirmed, cytogenetic remission (Figure 2b) [9].

Azacitidine maintenance treatment was assigned and the scheduled SCT was postponed. A total of 9 cycles of this treatment have been completed to date. The treatment was conducted in outpatient settings and the only observed side effect of transient neutropenia was perichondritis of the right ear auricle which was quickly resolved with IV antibiotics.

Experience from our case indicated that the loss of the Y chromosome was related to the disease onset. Our results showed that that a cytogenetic profile is the most important predictor of a response in MDS patients treated with Azacitidine which indicates that Azacitidine might be considered as an effective treatment for MDS cases associated with a favorable cytogenetic profile. Also, the experience with case shows that molecular analyses of the most predictive cytogenetic abnormalities in MDS could be a powerful diagnostic tool.

References

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. *N Engl J Med*. 2009;361(19):1872-85.
2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood*. 2002;100(7):2292-302.
3. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. *J Clin Oncol*. 2007;25(23):3503-10.
4. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood*. 1997;89(6):2079-88.
5. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*. 2012;120(12):2454-65.
6. A Pardanani, A Tefferi. Cytogenetic risk stratification in myelodysplastic syndromes: Are we there yet? *J Clin Oncol*. 2012;30(21):2703-4.
7. Wong AK, Fang B, Zhang L, Guo X, Lee S, Schreck R. Loss of the Y Chromosome An Age-Related or Clonal Phenomenon in Acute Myelogenous Leukemia/Myelodysplastic Syndrome? *Arch Pathol Lab Med*. 2008;132(8):1329-32.
8. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009;10(3):223-32.
9. Plaseski T, Noveski P, Trivodalieva S, Efremov GD, Plaseska-Karanfilska D. Quantitative fluorescent-PCR detection of sex chromosome aneuploidies and AZF deletions/duplications. *Genet Test*. 2008;12(4):595-605.
10. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood*. 2015;126(1):9-16.
11. Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. *Blood*. 2011;117(2):403-11.
12. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. *Blood*. 2006; 108(2):419-25.